Medifast's Q2 results show challenges related to weak customer acquisition. However, it is prioritizing efforts to enhance coach productivity in the near term.
Medifast, Inc. (NYSE:MED ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Steven Zenker - Vice President, Investor Relations Dan Chard - Chairman and Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants James Salera - Stephens Linda Bolton-Weiser - D.A. Davidson Operator Greetings and welcome to the Medifast Fourth Quarter 2024 Earnings Conference Call.
Medifast (MED) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.27 per share. This compares to earnings of $1.09 per share a year ago.
MED's new OPTAVIA ASCEND product line combines high-protein meals, fiber-rich nutrients and personalized coaching.
MED is battling customer acquisition challenges and high SG&A costs, while its strategic growth efforts keep it well-positioned for long-term success.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Medifast's Q3 results lower earnings and revenues, highlighting challenges in customer acquisition. Management issues soft guidance for the fourth quarter.
Medifast, Inc. (NYSE:MED ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Steven Zenker - Vice President-Investor Relations Dan Chard - Chairman & Chief Executive Officer Jim Maloney - Chief Financial Officer Conference Call Participants Jim Salera - Stephens Inc. Linda Bolton-Weiser - D.A. Davidson Operator Greetings, and welcome to the Medifast Third Quarter 2024 Earnings Conference Call.
MED is striving to excel in the evolving weight loss market where GLP-1 medication adoption is reshaping the industry dynamics amid macroeconomic challenges.
LOS ANGELES, CA / ACCESSWIRE / September 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Medifast, Inc. ("Medifast" or "the Company") (NYSE:MED) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.